Ajooni Biotech Limited (AJOONI) AI Stock Analysis

Ajooni Biotech Limited

(NSE:AJOONI)

Select Model

Rating:62Neutral

Price Target:INR 3.00▲(4.53% Upside)

Action:downgraded

Date:10/13/26

Strongest influence comes from mixed financial results with solid growth offset by cash flow concerns. Technical weakness adds downward pressure, while fair valuation provides modest support.

Positive Factors

Strong Revenue GrowthFY2026 revenue growth of about 44% after steady prior-year gains indicates expanding sales scale across the company’s animal-health and nutrition activities. If sustained, this can broaden operating reach and create a stronger base for future earnings, even though margins remain modest.

Negative Factors

Persistent Cash BurnFour consecutive years of negative operating cash flow, alongside sharply worsening free cash flow in FY2026, shows that reported earnings are not converting into cash. Persistent cash burn can constrain self-funded growth and increase reliance on financing unless working-capital or investment demands improve.

Ajooni Biotech Limited (AJOONI) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 494.34M
Dividend Yield: ―
Average Volume (3M): 320.24K
Price to Earnings (P/E): 12.8
Beta (1Y): 1.03
Revenue Growth: 78.39%
EPS Growth: 15.76%
Country: India
Employees: 182
Sector: General
Sector Strength: 55
Industry: Packaged Foods

Ajooni Biotech Limited Business Overview & Revenue Model

Company Description

Founded in 2010, Ajooni Biotech Limited is an Indian enterprise primarily engaged in the production and distribution of animal nutrition products. Headquartered in Mohali, India, the company's offerings encompass specialized cattle feeds and various...

How the Company Makes Money

Ajooni Biotech Limited primarily makes money by selling animal health and nutrition products (and related livestock/poultry-focused inputs) through its sales and distribution channels to customers in the animal husbandry ecosystem (e.g., farms, distr...

Ajooni Biotech Limited Financial Statement Overview

Summary

Robust revenue and net income growth with a strengthening balance sheet and lower leverage are offset by persistently negative operating and free cash flows, indicating liquidity risks.

Income Statement

88Very Positive

Balance Sheet

82Very Positive

Cash Flow

35Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	2.15B	1.82B	1.15B	801.15M	744.88M	740.38M
Gross Profit	303.98M	276.71M	138.13M	97.65M	87.45M	100.24M
EBITDA	76.80M	62.56M	57.57M	44.27M	30.60M	31.12M
Net Income	39.59M	43.22M	32.38M	21.61M	11.25M	10.49M
Balance Sheet
Total Assets	1.25B	1.20B	950.51M	475.20M	587.31M	290.18M
Cash, Cash Equivalents and Short-Term Investments	3.74M	4.19M	68.30M	4.30M	4.93M	573.86K
Total Debt	269.11M	177.63M	19.40M	21.68M	51.77M	53.50M
Total Liabilities	332.86M	291.74M	69.72M	48.12M	170.62M	126.35M
Stockholders Equity	916.23M	911.91M	880.79M	427.08M	416.69M	163.82M
Cash Flow
Free Cash Flow	18.31M	-232.32M	-192.16M	-95.54M	-84.39M	15.60M
Operating Cash Flow	135.46M	-52.03M	-171.84M	-39.52M	-55.79M	36.84M
Investing Cash Flow	-122.77M	-170.31M	-171.34M	76.37M	-158.24M	-18.97M
Financing Cash Flow	71.88M	158.23M	248.26M	-35.66M	216.55M	-19.73M

Ajooni Biotech Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price2.87

Price Trends

50DMA3.29Negative

100DMA3.58Negative

200DMA3.93Negative

Market Momentum

MACD-0.11Negative

RSI36.10Neutral

STOCH48.38Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AJOONI, the sentiment is Negative. The current price of 2.87 is below the 20-day moving average (MA) of 2.98, below the 50-day MA of 3.29, and below the 200-day MA of 3.93, indicating a bearish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 36.10 is Neutral, neither overbought nor oversold. The STOCH value of 48.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:AJOONI.

Ajooni Biotech Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:AJOONI against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:PARAGMILK	75Outperform	INR 29.22B	22.12	―	0.47%	10.91%	3.74%
IN:SKMEGGPROD	68Neutral	INR 10.24B	9.76	―	0.64%	21.31%	89.98%
IN:AVANTIFEED	66Neutral	INR 89.82B	16.46	―	1.52%	11.35%	-8.27%
IN:AJOONI	62Neutral	INR 520.17M	12.76	―	―	78.39%	15.76%
IN:MUKKA	60Neutral	INR 7.38B	10.54	―	―	76.01%	59.13%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:MKPL	47Neutral	INR 1.48B	29.54	―	―	17.76%	-50.16%

* General Sector Average

Performance Comparison

IN:AJOONI and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:AJOONI	Ajooni Biotech Limited	2.87	-2.27	-44.16%
IN:AVANTIFEED	Avanti Feeds Limited	659.25	-38.14	-5.47%
IN:MKPL	M K Proteins Limited	3.93	-2.80	-41.60%
IN:MUKKA	Mukka Proteins Limited	24.60	-0.47	-1.87%
IN:PARAGMILK	Parag Milk Foods Ltd.	232.80	-85.91	-26.96%
IN:SKMEGGPROD	SKM Egg Products Export (India) Ltd.	194.50	-17.87	-8.42%

Ajooni Biotech Limited Corporate Events

Ajooni Biotech Confirms SEBI-Compliant Corporate Website Now Fully Functional

Oct 19, 2026

Ajooni Biotech Limited has notified the National Stock Exchange of India that its corporate website has been updated and is now fully functional in line with Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 13, 2026

Ajooni Biotech Limited AI Stock Analysis